Maxalt
Product Images NDC 54868-4251

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Maxalt (NDC 54868-4251). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (Maxalt Tablets)

MAXALT-MLT 10MG packaging label distributed by Physicians Total Care, Inc. in Tulsa, OK. The label includes lot number 000, expiration date 01/60, manufacturer information for Merck & Company, Inc. in Whitehouse Station, NJ, and a barcode with the number 42510030000.*

FDA Label Image

Principal Display Panel (Maxalt-MLT Tablets)

The packaging label for MAXALT-MLT 10 mg tablets distributed by Physicians Total Care, Inc. It includes the NDC 54868-4499-0, lot number 000, and an expiration date of 01/60. The label also shows the manufacturer as Merck & Company, Inc., Whitehouse Station, NJ, and includes a barcode.*

FDA Label Image

Image Of Rizatriptan Benzoate Chemical Structure (Maxalt 01)

Chemical structure diagram depicting the molecular composition of the active ingredient in MAXALT-MLT by Physicians Total Care, Inc. The structure features multiple rings including a triazole and an indole, along with a phenyl group containing a carboxyl functional group.*

FDA Label Image

Image Of Figure 1 (Maxalt 02)

A line chart showing the estimated probability of response over time in hours post-dose. The chart compares placebo with MAXALT 5 mg and MAXALT 10 mg, illustrating increasing response rates up to 2 hours after dosing.*

FDA Label Image

Image Of Figure 2 (Maxalt 03)

A line chart depicting the estimated probability of remission or rescue over 24 hours post-dose for MAXALT-MLT 5 mg, MAXALT-MLT 10 mg, and placebo. The x-axis represents hours post-dose, and the y-axis shows the probability percentage, with three lines indicating different treatments' outcomes over time.*

FDA Label Image

Image Of Figure 3 (Maxalt 04)

A line graph displaying the estimated probability of response over time in hours post-dose for MAXALT-MLT 5 mg, MAXALT-MLT 10 mg, and placebo groups. The x-axis represents hours post-dose from 0 to 2, while the y-axis shows the estimated probability of response from 0% to 100%. The graph compares the effectiveness of different doses of MAXALT-MLT against placebo.*

FDA Label Image

Image Of Figure 4 (Maxalt 05)

A line graph showing the estimated probability of remediation or rescue over 24 hours post-dose for MAXALT-MLT at 5 mg and 10 mg doses compared to placebo. The x-axis represents hours post-dose, and the y-axis shows the probability percentage. MAXALT-MLT doses display an increasing effect over time relative to placebo.*

FDA Label Image

Image Of Figure 5 (Maxalt 06)

A line graph comparing the percentage response over time between MAXALT-MLT and placebo. The x-axis represents hours post stage 2 dose (0.5 to 2 hours), and the y-axis shows the percent response with 95% confidence intervals. MAXALT-MLT displays a higher percentage response than placebo at all measured times.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.